Strategies for Recurrent Colorectal Liver Metastases Based on Prognostic Factors and Resectability: Potential Benefit of Multidisciplinary Treatment.

IF 3.4 2区 医学 Q2 ONCOLOGY Annals of Surgical Oncology Pub Date : 2024-11-23 DOI:10.1245/s10434-024-16491-3
Kosuke Kobayashi, Yosuke Inoue, Atsushi Oba, Yoshihiro Ono, Hiroki Osumi, Takafumi Sato, Hiromichi Ito, Yoshihiro Mise, Eiji Shinozaki, Kensei Yamaguchi, Akio Saiura, Yu Takahashi
{"title":"Strategies for Recurrent Colorectal Liver Metastases Based on Prognostic Factors and Resectability: Potential Benefit of Multidisciplinary Treatment.","authors":"Kosuke Kobayashi, Yosuke Inoue, Atsushi Oba, Yoshihiro Ono, Hiroki Osumi, Takafumi Sato, Hiromichi Ito, Yoshihiro Mise, Eiji Shinozaki, Kensei Yamaguchi, Akio Saiura, Yu Takahashi","doi":"10.1245/s10434-024-16491-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Colorectal liver metastasis (CLM) is classified into technical and oncologic categories, with recommended treatments for each resectability category. However, the classification of recurrent CLM has not been established to date.</p><p><strong>Methods: </strong>This study evaluated patients with CLM who underwent initial liver resection between 2006 and 2020 and subsequently experienced liver recurrence. Long-term outcomes and prognostic factors associated with recurrent CLM were investigated.</p><p><strong>Results: </strong>From 949 patients who underwent an initial liver resection, the analysis included 392 patients with liver recurrence. Repeat liver resection was associated with a significantly longer prognosis than non-resection (5-year overall survival [OS] from initial liver resection: 66.3 % vs 27.2 %, p < 0.0001). Multivariable analysis indicated the following independent prognostic factors: four or more recurrent tumors (p = 0.015), tumor 5 cm or larger in size (p = 0.004), and presence of extrahepatic diseases (p = 0.003). The patients were stratified into resectable, borderline resectable, and unresectable recurrent CLM groups based on these criteria. The prognosis varied significantly across the groups, with 5-year OS rates of 67.3 % for resectable recurrent CLM, 30.8 % for borderline resectable recurrent CLM, and 2.6 % for unresectable recurrent CLM (p < 0.0001). Patients with borderline resectable recurrent CLM who did not receive adjuvant chemotherapy after initial liver resection had a positive prognostic impact of preoperative chemotherapy (p = 0.049).</p><p><strong>Conclusion: </strong>The significant independent predictors of recurrent CLM prognosis were four or more tumors, tumor size of 5 cm or larger, and the presence of extrahepatic diseases at recurrence. It is critical to onsider the current condition and tumor resectability at the time of recurrence, and tailored treatments could further improve recurrent CLM outcomes.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1245/s10434-024-16491-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Colorectal liver metastasis (CLM) is classified into technical and oncologic categories, with recommended treatments for each resectability category. However, the classification of recurrent CLM has not been established to date.

Methods: This study evaluated patients with CLM who underwent initial liver resection between 2006 and 2020 and subsequently experienced liver recurrence. Long-term outcomes and prognostic factors associated with recurrent CLM were investigated.

Results: From 949 patients who underwent an initial liver resection, the analysis included 392 patients with liver recurrence. Repeat liver resection was associated with a significantly longer prognosis than non-resection (5-year overall survival [OS] from initial liver resection: 66.3 % vs 27.2 %, p < 0.0001). Multivariable analysis indicated the following independent prognostic factors: four or more recurrent tumors (p = 0.015), tumor 5 cm or larger in size (p = 0.004), and presence of extrahepatic diseases (p = 0.003). The patients were stratified into resectable, borderline resectable, and unresectable recurrent CLM groups based on these criteria. The prognosis varied significantly across the groups, with 5-year OS rates of 67.3 % for resectable recurrent CLM, 30.8 % for borderline resectable recurrent CLM, and 2.6 % for unresectable recurrent CLM (p < 0.0001). Patients with borderline resectable recurrent CLM who did not receive adjuvant chemotherapy after initial liver resection had a positive prognostic impact of preoperative chemotherapy (p = 0.049).

Conclusion: The significant independent predictors of recurrent CLM prognosis were four or more tumors, tumor size of 5 cm or larger, and the presence of extrahepatic diseases at recurrence. It is critical to onsider the current condition and tumor resectability at the time of recurrence, and tailored treatments could further improve recurrent CLM outcomes.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基于预后因素和可切除性的复发性结直肠癌肝转移策略:多学科治疗的潜在益处。
背景:结直肠肝转移(CLM)被分为技术和肿瘤学两类,每类可切除性都有推荐的治疗方法。然而,复发性大肠肝转移瘤的分类至今尚未确立:本研究评估了2006年至2020年间接受初次肝脏切除术并随后出现肝脏复发的CLM患者。结果:949 名接受肝脏切除术的 CLM 患者中,有 1.2% 的患者在术后出现肝脏复发:从949名接受首次肝脏切除术的患者中,分析包括了392名肝脏复发患者。与未切除肝脏的患者相比,再次切除肝脏的患者预后明显更长(初次肝脏切除术后的5年总生存率[OS]:66.3% vs 27.2%):66.3%对27.2%,P<0.0001)。多变量分析显示了以下独立预后因素:四个或更多复发肿瘤(p = 0.015)、肿瘤大小为 5 厘米或更大(p = 0.004)以及存在肝外疾病(p = 0.003)。根据这些标准将患者分为可切除组、边缘可切除组和不可切除复发性 CLM 组。各组的预后差异显著,可切除复发性 CLM 的 5 年 OS 率为 67.3%,边缘可切除复发性 CLM 为 30.8%,不可切除复发性 CLM 为 2.6%(p < 0.0001)。首次肝脏切除术后未接受辅助化疗的边缘可切除复发性CLM患者术前化疗对预后有积极影响(p = 0.049):结论:复发CLM预后的重要独立预测因素是四个或更多肿瘤、肿瘤大小为5厘米或更大以及复发时存在肝外疾病。考虑复发时的现状和肿瘤的可切除性至关重要,有针对性的治疗可进一步改善复发 CLM 的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.90
自引率
10.80%
发文量
1698
审稿时长
2.8 months
期刊介绍: The Annals of Surgical Oncology is the official journal of The Society of Surgical Oncology and is published for the Society by Springer. The Annals publishes original and educational manuscripts about oncology for surgeons from all specialities in academic and community settings.
期刊最新文献
Correction: The Top Ten Annals of Surgical Oncology Original Articles on Twitter/X: 2020-2023. Correction: ASO Author Reflections: Minimally Invasive Surgery, Three-Dimensional (3D) Reconstruction and Indocyanine Green Fluorescence: The Perfect Combo to Enter the Era of Intraoperative Liver Navigation. Correction: Patient-Reported Outcomes 10 Years After Breast-Conserving Surgery for Early-Stage Breast Cancer. ASO Visual Abstract: Evaluating the Efficacy of Different Treatment Intensities in Nasopharyngeal Carcinoma Patients: A Nationwide Cancer Registry-Based Study. ASO Visual Abstract: Cost-Analysis of Pelvic Exenteration Surgery for Advanced Pelvic Malignancy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1